



Technical Bulletin

Genotyping for HIV Drug Resistance includes Integrase Inhibitors

TO: Medical Staff and Clients

FROM: Dr. Amy Woron, PhD, MPH
V.P. - Technical Director (Microbiology/Molecular)

Tori Enomoto, M(ASCP)
Manager, DLS Microbiology

Dr. Wesley Kim, MD
Medical Director DLS
and QMC West

Dr. Ana Ortega-Lopez, MD
Medical Director QMC Punchbowl,
North Hawaii and Molokai

DATE: Revalidated September 22, 2026

SUBJECT: Mutations associated with integrase inhibitor resistance are included in HIV genotyping

Genotyping of HIV-1 is performed by sequencing reverse transcriptase and protease genes to identify mutations associated with resistance to those treatment regimens. This genotyping includes detection of mutations associated with resistance to integrase inhibitors (e.g., raltegravir, elvitegravir, dolutegravir). In general, testing is performed in:

1. Treatment-naïve patients prior to initiation of antiretroviral therapy.
2. HIV-1 patients failing antiretroviral regimens containing RT, PR or Integrase inhibitors.

This test is performed at Quest Diagnostics. It was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and can be used for clinical purposes.

DLS ordering code: 6013 HIV-1 Genotype (RTI, PI, Integrase Inhibitors)

Please refer any questions to Tori Enomoto, Manager - DLS Microbiology Laboratory at 808- 441-5470, or DLS Client Services at 589-5101.

Diagnostic Laboratory Services Inc.
99-859 Iwaiwa Street – Aiea, HI 96701
(808) 589-5100 – www.dlslab.com